For the year ending 2025-12-31, TBPH had $130,009K increase in cash & cash equivalents over the period. $238,499K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Loss from operations | -3,602 |
| Net gain on realized contingent milestone and royalty assets | 75,137 |
| Trelegy milestone income | 50,000 |
| Interest expense (non-cash) | 2,461 |
| Interest and other income, net | 10,173 |
| Provision for income tax benefit (expense) | 23,352 |
| Net income (loss) | 105,895 |
| Depreciation and amortization | 1,626 |
| Amortization and accretion on investment securities, net | 2,830 |
| Future royalty payment contingency interest accretion | 2,461 |
| Share-based compensation | 18,476 |
| Loss on disposal of property and equipment | -35 |
| Amortization of right-of-use assets | 4,015 |
| Deferred income taxes | -11,519 |
| Other | 89 |
| Receivables from collaborative and licensing arrangements | 27,099 |
| Prepaid clinical and development services | -73 |
| Other prepaid and current assets | 3,360 |
| Right-of-use lease assets | 32 |
| Future contingent milestone and royalty assets | -144,200 |
| Other assets | 1,077 |
| Accounts payable | 326 |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | 4,009 |
| Operating lease liabilities | -7,117 |
| Unrecognized tax benefits | 10,481 |
| Other long-term liabilities | 67 |
| Net cash provided by (used in) operating activities | 238,541 |
| Purchases of property and equipment | 42 |
| Purchases of marketable securities | 248,217 |
| Maturities of marketable securities | 142,975 |
| Net cash (used in) provided by investing activities | -105,284 |
| Proceeds from the sale of ordinary shares | 20 |
| Proceeds from option exercises | 766 |
| Repurchase of shares to satisfy tax withholding | 4,034 |
| Net cash used in financing activities | -3,248 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 130,009 |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,633 |
| Cash, cash equivalents, and restricted cash at end of period | 168,642 |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)